Relmada Therapeutics (RLMD)
(Delayed Data from NSDQ)
$3.51 USD
+0.01 (0.29%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.49 -0.02 (-0.57%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.51 USD
+0.01 (0.29%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.49 -0.02 (-0.57%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth C Momentum C VGM
Zacks News
Relmada Therapeutics (RLMD) Loses -43.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Relmada Therapeutics (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Relmada (RLMD) Up on Positive Data for Anti-Depressant Candidate
by Zacks Equity Research
Relmada's (RLMD) shares rise on long-term efficiency and safety data from the phase III study of its lead candidate REL-1017 to treat patients with major depressive disorder.
Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More
by Zacks Equity Research
Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week.
Relmada (RLMD) Lead Candidate Fails Late-Stage Depression Study
by Zacks Equity Research
Relmada's (RLMD) phase III study, evaluating REL-1017 in major depressive disorder, fails to achieve statistical significance. Shares plunge 80% following the news.
Wall Street Analysts See a 231% Upside in Relmada Therapeutics, Inc. (RLMD): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Relmada Therapeutics, Inc. (RLMD) points to a 231.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Sage, Biogen Plan to File Zuranolone NDA for MDD in 2022
by Zacks Equity Research
Sage (SAGE) and partner Biogen are looking to get approval for zuranolone as an oral treatment for major depressive disorder. They will start rolling submission of an NDA in early 2022 for the candidate.
Catalyst (CPRX) Up More Than 20% in Past 3 Months: Here's Why
by Zacks Equity Research
Catalyst's (CPRX) lead drug, Firdapse, is approved for treating Lambert-Eaton myasthenic syndrome. The drug has seen solid uptake since its launch.
Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) earnings and revenues beat estimates in the second quarter of 2021. The company raised its financial guidance for 2021.
Down 22.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Relmada Therapeutics, Inc. (RLMD)
by Zacks Equity Research
Relmada Therapeutics, Inc. (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Is the Options Market Predicting a Spike in Relmada (RLMD) Stock?
by Zacks Equity Research
Investors need to pay close attention to Relmada (RLMD) stock based on the movements in the options market lately.
New Strong Sell Stocks for October 23rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.